Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders

Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders

The adverse effects of smoking cessation in individuals with mental health disorders have been a point of concern, and progress in the development of treatment has been slow. The primary first-line treatments for smoking cessation are Nicotine Replacement Therapy, Bupropion, Varenicline, and behavio...

Full description

Saved in:
Bibliographic Details
Published in:International review of psychiatry (Abingdon, England) Vol. 35; no. 5-6; pp. 397 - 417
Main Authors: Castaldelli-Maia, João Mauricio, Camargos de Oliveira, Victoria, Irber, Flávia Mariana, Blaas, Israel K, Angerville, Bernard, Sousa Martins-da-Silva, Anderson, Koch Gimenes, Gislaine, Waisman Campos, Marcela, Torales, Julio, Ventriglio, Antonio, Guillois, Carine, El Ouazzani, Houria, Gazaix, Léna, Favré, Pascal, Dervaux, Alain, Apter, Gisèle
Format: Journal Article
Language:English
Published: England Taylor & Francis Ltd 18-08-2023
Subjects:
Benzazepines - adverse effects
Bupropion
Clinical outcomes
Clonidine
Drugs
Efficacy
Humans
Mental disorders
Mental Health
Nicotine
Nicotine replacement therapy
Nicotinic Agonists - adverse effects
Psychopharmacology
Psychotropic drugs
Quinoxalines - adverse effects
Side effects
Smoking - drug therapy
Smoking Cessation
Substance abuse
Substance Withdrawal Syndrome - drug therapy
Symptoms
Tobacco Use Cessation Devices
Withdrawal symptoms
psychopharmacology
mental health
cessation
Smoking
interactions
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The adverse effects of smoking cessation in individuals with mental health disorders have been a point of concern, and progress in the development of treatment has been slow. The primary first-line treatments for smoking cessation are Nicotine Replacement Therapy, Bupropion, Varenicline, and behavioural support. Nortriptyline and Clonidine are second-line treatments used when the first-line treatments are not effective or are contraindicated. Smoking cessation medications have been shown to be effective in reducing nicotine cravings and withdrawal symptoms and promoting smoking cessation among patients living with mental disorders. However, these medications may have implications for patients' mental health and need to be monitored closely. The efficacy and side effects of these medications may vary depending on the patient's psychiatric condition, medication regimen, substance use, or medical comorbidities. The purpose of this review is to synthesise the pharmacokinetics, pharmacodynamics, therapeutic effects, adverse effects, and pharmacological interactions of first- and second-line smoking cessation drugs, with an emphasis on patients suffering from mental illnesses. Careful consideration of the risks and benefits of using smoking cessation medications is necessary, and treatment plans must be tailored to individual patients' needs. Monitoring symptoms and medication regimens is essential to ensure optimal treatment outcomes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0954-0261
1369-1627
DOI:10.1080/09540261.2023.2249084